HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prednisone versus placebo in membranoproliferative glomerulonephritis: long-term clinicopathological correlations.

Abstract
Eighteen children with primary MPGN were included in a double blind controlled study. Experimental group received prednisone and control group received lactose. Studies of renal biopsy on admission, at 3 yr (17 pt) and 5 yr (8 pt) were performed. Mean time of observation in both groups was similar (6.5 yr). Four patients of the control group developed ESRD and none of the experimental group. Two patients of the control and one of the experimental group remitted. Serial immunopathological studies showed decreasing mesangial cellularity, thickening of the capillary walls and deposits in both groups. Increase tubulointerstitial alterations and percentage of global sclerotic glomeruli was generally observed except in cases in whom proteinuria disappeared. Our results suggest that prednisone therapy may retard the development of ESRD in children with MPGN. However, longer periods of observation and greater number of cases are necessary to confirm if this treatment in useful.
AuthorsF Mota-Hernandez, G Gordillo-Paniagua, R Muñoz-Arizpe, J A Lopez-Arriaga, L Barboza-Madueño
JournalThe International journal of pediatric nephrology (Int J Pediatr Nephrol) 1985 Jan-Mar Vol. 6 Issue 1 Pg. 25-8 ISSN: 0391-6510 [Print] Italy
PMID3888886 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Prednisone
Topics
  • Adolescent
  • Biopsy
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Glomerulonephritis (complications, drug therapy, pathology)
  • Humans
  • Hypertension (etiology)
  • Kidney Failure, Chronic (etiology)
  • Male
  • Prednisone (therapeutic use)
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: